Epithelial salivary gland tumours. An immunohistological and prognostic investigation

Therkildsen, Marianne Hamilton

doi:10.1111/j.1600-0463.1999.tb05379.x

Cited by 3 publications

(3 citation statements)

References 212 publications

(221 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 18 Histologically, 95% of salivary gland tumors are of epithelial origin. 19 However, these neoplasms exhibit one of the most complex and diverse array of histopathological presentations of any human tumor, as evidence by the number of World Health Organization classifications.…”

Section: Discussionmentioning

confidence: 99%

Molecular Differences in Mucoepidermoid Carcinoma and Adenoid Cystic Carcinoma of the Major Salivary Glands

et al. 2001

View full text Add to dashboard Cite

There is a clear difference in the molecular phenotypes of MEC and ACC. The lack of statistically significant expression in ACC, when compared with similar uninvolved salivary gland tissue, suggests minimal involvement for these molecular structures in the pathogenesis of ACC. Conversely, erbB-2, erbB-3, EGFR, and TGF-alpha may have a role in the development and progression of MEC. These results have therapeutic implications for MEC of the major salivary glands.

show abstract

Section: Discussionmentioning

confidence: 99%

Molecular Differences in Mucoepidermoid Carcinoma and Adenoid Cystic Carcinoma of the Major Salivary Glands

et al. 2001

View full text Add to dashboard Cite

show abstract

“…Moreover, sialyl-T and T antigen can be used as biomarkers in progression of several carcinomas [36–49]. The antigens have been found to be expressed in gastric carcinomas such as colon cancer [37, 39], breast carcinomas [43, 50], salivary gland carcinomas [38, 45–49], cancer of the human cervix [36], pancreatic tumors [42], ovarian tumors [44] and skin tumors [40, 41]. Since many of these cell types also over-express CD24 [20–22], it is intriguing that the CD24 over-expression may account for the increased sialyl-T in the cancer cells.…”

Section: 0 Results and Discussionmentioning

confidence: 99%

Analysis of Recombinant CD24 Glycans by MALDI-TOF-MS Reveals Prevalence of Sialyl-T Antigen

Motari¹,

Zheng²,

Su³

et al. 2009

Am. J. Biomed. Sci.

View full text Add to dashboard Cite

CD24 is a glycosyl-phosphatidyl-inositol linked glycoprotein expressed in a broad range of cell types and is heavily glycosylated. It has been found to be over expressed in cancers and tumors and is also a costimulatory molecule. Therefore, this study was carried out to define the structures of the carbohydrates associated with the CD24 recombinant protein. The CD24 glycoprotein's oligosaccharides were released by chemical and enzymatic means prior to being analyzed by MALDI-TOF-MS. The results obtained showed that CD24 is both N-and O-glycosylated. The major oligosaccharides were found to be Neu5Acα-2,3/6Galβ-1,3GalNAc, NeuAc 2 Gal β-1,3GalNAc 1 (O-glycans), GalNAc 2 GlcNAc 2 Man 3 Fuc 1 , Gal 1 GalNAc 2 GlcNAc 2 Man 3 Fuc 1 , and Gal 2 GalNAc 2 GlcNAc 2 Man 3 Fuc 1 (N-glycans). The results showed that Neu5Acα-2,3/6Galβ-1,3GalNAc (sialyl-tumor antigen, sT), a cancer-associated carbohydrate, was the most abundant glycan associated with CD24. This result raised the intriguing possibility that CD24 may be a major carrier of the sialyl-T abundantly found in cancer cells. Keywords CD24; Glycans; MALDI-TOF-MS; T antigen IntroductionCD24 is a glycosyl-phosphatidyl-inositol (GPI)-anchored glycoprotein with widespread expression in both hematopoietic and non-hematopoietic cells. The protein is composed of 27-35 amino acids with nearly half of the amino acids being serine and threonine [1,2]. Both serine and threonine are potential sites for O-glycosylation and asparagine gives potential for N-glycosylation. The human form of CD24 has an unusual structure with the core having [3]. The CD24 molecule is expressed in developing or regenerating tissue and in pre-B-cells, granulocytes, keratinocytes, and renal tubular epithelial cells [1,4,5]. CD24 is over-expressed in both hematological malignancies and a variety of solid tumors such as gastric, renal, nasopharyngeal, hepatocellular, colonic, and small cell lung carcinomas [6,7].The CD24 gene has been implicated in immunity, cancer and autoimmune diseases. Thus, expressing of CD24 in non-professional antigen-presenting cells, such as activated B cells [8,9], astrocytes and oligodendritic cells [10,11] conveys a potent costimulatory activity. In T cells, CD24 promotes homeostatic proliferation [12]. In contrast, CD24 expression in dendritic cells is a negative regulator that modulates the pace of homeostatic proliferation [13], a process that is important for development of autoimmune diseases and cancer immunotherapy [14,15]. Expression of CD24 in pre-B cells on the other hand, modulates fibronectin/VLA-4:VCAM-1 interactions [16,17]. Outside the immune system, CD24 expressed in the central nervous system (CNS) has been shown to inhibit neurite growth [18]. In humans, CD24 polymorphism controls risk and progression of autoimmune diseases, such as multiple sclerosis [19]. Concerning cancerous cells, CD24 has been found to be prevalent on many tumors and carcinomas [20][21][22]. Carbohydrates of CD24 on tumor cells have been shown to play an important role in metastasi...

show abstract

“…The expression of simple mucin-type carbohydrate antigens (including T, Tn, sialosyl-Tn) has been extensively studied in both normal salivary gland tissues and salivary gland tumors (8)(9)(10)(11). There are, however, only few conflicting reports on the expression of MUC1 and MUC2 in non-neoplastic salivary gland tissue (5,6,(12)(13)(14).…”

mentioning

confidence: 99%

MUC1 and MUC2 expression in salivary gland tumors and in non‐neoplastic salivary gland tissue

Mannweiler

Beham

Langner

2003

APMIS

View full text Add to dashboard Cite

The expression of MUC1 and MUC2 was studied in salivary gland tumors and non-neoplastic salivary gland tissue. Formalin-fixed paraffin-embedded specimens from 101 patients (21 pleomorphic adenomas (PA), 22 Warthin's tumors (WT), 26 adenoid cystic carcinomas (ACC), 13 acinic cell adenocarcinomas (ACA), 9 mucoepidermoid carcinomas (MC), and 10 specimens of non-neoplastic parotid and submandibular gland tissue) were immunostained. All salivary gland tumors expressed MUC1. A strong immunoreactivity was noted in WT and MC, a moderate in ACC and ACA, and a weak in PA. Strong expression of MUC2 was noted in all WT, moderate expression in MC, and weak expression in PA and ACA. All cases of ACC except for two were negative for MUC2. In general, MUC1 expression was stronger than that of MUC2. Non-neoplastic salivary gland tissue revealed a moderate MUC1 and MUC2 expression in excretory ducts and a strong expression in striated ducts. The apical plasma membrane of some serous acini expressed MUC1. Mucous acini were negative for both antigens. No change in immunoreactivity was noted in cases of chronic sclerosing sialadenitis. In conclusion, the different expression pattern of MUC1 and MUC2 in salivary gland neoplasia may be of additional value for the classification of salivary gland tumors.

show abstract

Epithelial salivary gland tumours. An immunohistological and prognostic investigation

Cited by 3 publications

References 212 publications

Molecular Differences in Mucoepidermoid Carcinoma and Adenoid Cystic Carcinoma of the Major Salivary Glands

Molecular Differences in Mucoepidermoid Carcinoma and Adenoid Cystic Carcinoma of the Major Salivary Glands

Analysis of Recombinant CD24 Glycans by MALDI-TOF-MS Reveals Prevalence of Sialyl-T Antigen

MUC1 and MUC2 expression in salivary gland tumors and in non‐neoplastic salivary gland tissue

Contact Info

Product

Resources

About